Kimmtrak (tebentafusp), a bispecific protein for the treatment of uveal melanoma, has received three more regulatory approvals on the back of clinical data showing that it extends overall survival in patients with the rare and aggressive form of melanoma. Approvals have been issued by regulatory authorities in the UK, Canada and Australia, the developer Immunocore Holdings Plc announced on 8 June. This follows approvals earlier in the year in the US and EU.
